Abstract:Following the publication of this article, an interested reader drew to the authors' attention that the flow cytometric (FCM) plots in Fig. 2A on p. 2278 showing the 'Dasatinib' and 'CA‐4' experiments were duplicates of each other. After having re‐examined their original data, and due to the overall similarity of the data, the authors have realized that these data were inadvertently assembled incorrectly in the figure. They realize that they also made a further mistake regarding the writing of the ratios of mitochondrial membrane‐depolarized HO‐8910 cells for these FCM plots (essentially, these were written the wrong way around): The percentage of mitochondrial membrane‐depolarized HO‐8910 cells should have been written as 22.50% for the dasatinib‐treated cells (the centre‐left FCM plot) and 15.71% for the CA‐4‐treated cells (centre‐right plot). A revised version of Fig. 2 now showing alternative data for the FCM experiments shown in Fig. 2A, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 2A did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree with the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for granting them this opportunity to publish a corrigendum. Furthermore, they apologize to the readership for any inconvenience caused. [Oncology Reports 29: 2275‐2282, 2013; DOI: 10.3892/or.2013.2405]

Correction to: A novel protein derived from lamprey supraneural body tissue with efficient cytocidal actions against tumor cells

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway (Journal of Experimental and Clinical Cancer Research (2018) 37 (53) DOI: 10.1186/s13046-018-0703-9)

Correction To: Novel Smac Mimetic APG-1387 Elicits Ovarian Cancer Cell Killing Through TNF-alpha, Ripoptosome and Autophagy Mediated Cell Death Pathway

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

[Corrigendum] Nucleosome‐binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2‐OS osteosarcoma cell lines

[Corrigendum] Antiproliferative effect of alpinetin in BxPC-3 pancreatic cancer cells

Corrigendum: Hollow Polypyrrole Nanospindles for Highly Effective Cancer Therapy

Erratum: Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

[Corrigendum] HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Corrigendum to "Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients"

Correction: Corrigendum: A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation

Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043

Correction To: Bilobalide Induces Neuronal Differentiation of P19 Embryonic Carcinoma Cells Via Activating Wnt/β-Catenin Pathway

Correction: A Novel Highly Potent Trivalent TGF-β Receptor Trap Inhibits Early-Stage Tumorigenesis and Tumor Cell Invasion in Murine Pten-deficient Prostate Glands

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‐4 in vitro and in vivo

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Correction: Corrigendum: Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukaemia Development

[Corrigendum] Angiopoietin‑like Protein2 Expression is Suppressed by Angiotensinii Via the Angiotensinii Type1 Receptor in Rat Cardiomyocytes